Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç, +157

The Lancet Oncology

Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy +4

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold, +187

The Lancet

Regenerative MedicineCell TherapyTransplantationMarrow TransplantationPlacebo-controlled Phase 3 +5

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Sonja Zweegman, Bronno van der Holt, Ulf‐Henrik Mellqvist, +25

Blood

Smoldering multiple myeloma risk factors for progression: a Danish population‐based cohort study

Rasmus Sørrig, Tobias Wirenfeldt Klausen, Morten Salomo, +11

European Journal Of Haematology

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Meletios Α. Dimopoulos, Katja Weisel, Philippe Moreau, +17

Leukemia

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population

Rasmus Sørrig, Tobias Wirenfeldt Klausen, Morten Salomo, +12

PLoS ONE

A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma

Markus Hansson, Peter Gimsing, Ashraf Badros, +16

Clinical Cancer Research

Risk factors for blood stream infections in multiple myeloma: A population‐based study of 1154 patients in Denmark

Rasmus Sørrig, Tobias Wirenfeldt Klausen, Morten Salomo, +2

European Journal Of Haematology

Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study

Rasmus Sørrig, Tobias Wirenfeldt Klausen, Morten Salomo, +2

European Journal Of Haematology

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

Lene Kongsgaard Nielsen, Claudia A.M. Stege, Birgit I. Lissenberg‐Witte, +27

Haematologica